Cardiff Oncology Inc
CRDF
Get informed when a big investor buys or sells
+ FollowMarket Cap$70.1M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $70.10 Million |
|---|---|
| Enterprise Value | $61.36 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.69 |
| Beta | 1.42 |
| Outstanding Shares | 68,397,000 |
Return
| Return on Equity | -151.00% |
|---|---|
| Return on Assets | -107.33% |
| Return on Invested Capital | -155.56% |
Valuation & Multiples
| P/E Ratio | -1.5 |
|---|---|
| PEG | 4.44 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 288.08 |
| Enterprise Value to EBIT | -1.49 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$62,778
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$67,222
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 9.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.23%▼ 26.19% |
|---|---|
| Total Invested | $1.02M▼ 95.81% |
| Investors Holding | 11▼ 99.00% |
ESG Score
No data
About Cardiff Oncology Inc
CEO: Mark Erlander